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Ever since the discovery of cancer stem cells in leukemia and, more recently, in solid tumors, enormous
attention has been paid to the apparent stem cell nature of cancer. These concepts were the focus of the
‘‘Stem Cells and Cancer’’ symposium held recently at the University of California, San Francisco, and the
inspiration for this overview of current research and important questions emerging in this area.This year’s annual UCSF Helen Diller Family Comprehensive
Cancer Center Symposium focused on stem cells and cancer.
This symposium provided a representation of all facets of stem
cell biology: from the role of stem and progenitor cells in devel-
opment to adult tissues, normal stem cells versus cancer stem
cells, diverse model organism systems, and translational stud-
ies. In the current era, postidentification of some types of cancer
stem cells, expectations surrounding the discovery of these
important cancer cells are high (for example, see Al-Hajj et al.,
2003; Reya et al., 2001; Wang, 2007). In particular, it is now pre-
sumed that we will be able to trace cancer’s normal cell of origin,
identify molecular pathways in tumorigenic subpopulations, not
just the bulk tumor sample, and most importantly, develop new
treatments that will lead to more durable and widespread cancer
cures by targeting cancer stem cells. We focus here on the
crucial questions raised during the insightful discussions that
took place at the meeting.
Cancer Stem Cells and Cells of Origin
One of the areas that remains an important, yet unanswered,
question is what are the normal cells of origin for cancer and their
relationship to cancer stem cells. A clear distinction was made in
several talks between the cells that give rise to the first form of
the tumor (cells of origin), which may be stem cells, progenitor
cells, or differentiated cells depending each tumor type, and
the cells that propagate the tumor phenotype and exhibit self-
renewal and differentiation capacity (cancer stem cells or tu-
mor-initiating cells). For example, Irving Weissman (Stanford
University, CA) showed his group’s viewpoint, illustrating how
different cell lineages in the hematopoietic system fit into the tra-
ditional multistep cancer progression model often referred to by
cancer biologists as the Vogelgram (Fearon and Vogelstein,
1990). According to the minimum seven-step ‘‘Weissmangram,’’
(Rossi et al., 2008) the earliest step on the path to hematopoietic
malignancies must take place in the hematopoietic stem cell
(HSC) population that exhibits the self-renewal properties and
longevity required for an accumulation and maintenance of mu-
tational events. The limited life span of progenitor cells combined
with their inability to self-renew precludes eventual cancer pro-
gression unless additional mutations or epigenetic events thatconfer these properties accumulate. When these additional
events occur in progenitor cell populations derived from mutant
HSC clones, cancer progression occurs. Thus, the phenotype of
the cancer stem cell may be more similar to the normal progen-
itor population than to the HSC itself. There is evidence that this
concept holds true in mouse models of solid cancer (Joseph
et al., 2008; Zheng et al., 2008). The mutations or epigenetic
events needed for this process include those that confer avoid-
ance of the immune response and apoptotic evasion, among
others. This model highlights the principle that the phenotype
of the cell of origin need not match that of the cancer stem cell.
These ideas are also in line with recent data from Michael
Clarke (Stanford University, CA), who showed that in mice triply
deficient in Trp53, Ink4a, and Arf expression, long-term hemato-
poietic engraftment is served by cells that phenotypically resem-
ble multipotent progenitors, cells that are not normally capable of
self-renewal (Akala et al., 2008). These data suggest that pro-
genitor cells can acquire self-renewal ability if they receive the
correct combination of genetic alterations. Normally, with pro-
gressive differentiation, there is restriction of self-renewal poten-
tial, but the combined loss of cell-cycle regulators allowed
self-renewal to be reinstated in more mature cells, such as multi-
potent progenitors, but not in cells further down the lineage hier-
archy, such as common myeloid progenitors. Also fitting with
this concept, data and questions from several talks, including
those from Sean Morrison (University of Michigan, Ann Arbor,
MI) and Meenhard Herlyn (Wistar Institute, Philadelphia, PA),
raised the possibility that the phenotype of the cancer stem
cell from early-stage lesions may be distinct from the phenotype
of cancer stem cells from advanced tumors.
The logical extension of this model, in that it combines cell and
molecular biology of cancer cells, was also one of the first
discussion points raised at the Symposium: the hard question
that arises is whether cancer stem cells, assuming they exist,
will be too difficult to target. More precisely, if the cancer stem
cell phenotype can change as tumors evolve, how can we expect
to successfully target this population to achieve more effective
therapy? Could the non-stem component of the cancer cell pop-
ulation evolve to acquire stem cell properties? The question was
posed with the assumption that during the initial stages of
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erogeneity can arise during tumor progression. Sean Morrison
pointed out that we do not yet know whether the events that
accumulate in the cancer stem cell subset, or the non-stem
cell component of the tumor population, arise due to epigenetic
or genetic mechanisms. Certainly, determining the relative de-
gree of reversible versus irreversible alterations will be important
to address this question. Gerard Evan (University of California,
San Francisco, CA) posed a related question, in that he ques-
tioned why only some cancer cells are self-renewing, and asked
what might distinguish the non-stem-like cells in a tumor that
might evolve to exhibit cancer stem cell activity from other sub-
sets that cannot? Finding a mechanistic basis for cancer stem
cell functions will be key advances required to answer these
important questions.
Cancer Signaling Pathways
Several key concepts that emerged during the meeting were
identified as crucial for our understanding of how molecular
pathways regulate normal tissue stem cells, cells of origin, and
cancer stem cells. One theme that reappeared in several presen-
tations is the importance of understanding the coordination of
different pathways in a particular stem cell type. While many
individual pathways have already been linked to stem cell regu-
lation, such as the Wnt, Hedgehog, Notch, Hippo, etc. cascades,
as demonstrated by Yuh Nung Jan (University of California, San
Francisco, CA), Thomas Rando (Stanford University, CA), Judith
Kimble (University of Wisconsin, Madison, WI), and many others
at the meeting and in published literature (reviewed in Blanpain
et al., 2007), it is clear that simply considering each pathway in
isolation will result in missing the big picture. Instead, we must
now consider that most of these pathways have coordinated
efforts and crosstalk. As Elaine Fuchs (Rockefeller University,
New York, NY) articulated, a number of these pathways may
function to reciprocally control stem cell activation versus stem
cell quiescence and tipping this balance may result in inappropri-
ate stem cell activation. As further discussed by Thomas Look
(Harvard Medical School and Dana-Farber Cancer Institute,
Boston, MA), the overlap of key molecular pathways and their
relationship to mutational patterns found in cancer cells has im-
portant implications for therapy. A detailed analysis of collateral
pathway defects in cancer is required to understand how stem
cells are regulated and to effectively treat cancer. For example,
use of gamma secretase inhibitors to inhibit activated Notch sig-
naling is unlikely have a therapeutic effect on tumors that have
deleted PTEN, given that in such cells, the Akt pathway domi-
nates control over the proliferative state. It likely will be useful
to combine multiple drugs that antagonize individual pathways
in order to target cancer stem cells. This goal is complicated
by the need to simultaneously ensure that the various signaling
cascades required for normal tissue homeostasis are maintained
intact and highlights a specific challenge facing the field.
A second emerging concept in attempts to elucidate stem cell
molecular control is that regulatory pathways and signaling
events are not simply on or off, but rather are fine-tuned with
thresholds to achieve a desired set point. Abrogation of stem
cell maintenance or function can occur both in settings of exces-
sive pathway stimulation and also in response to the complete
elimination of a pathway; the correct concentration and localiza-
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ity. This concept has been beautifully demonstrated in numerous
studies of morphogen gradients during development, and now is
relevant at minimum for the Wnt, Shh, and Bmp cascades, as de-
scribed by Thomas Rando, Arturo Alvarez-Buylla (University of
California, San Francisco, CA), Elaine Fuchs, and Ron DePinho
(Harvard Medical School and Dana-Farber Cancer Institute,
Boston, MA). Alvarez-Buylla’s work reveals that disruption of
a structural signaling hub, the primary cilium, through Kif3a
mutation blocks Shh signaling and results in defects in the
proliferative zones of the mouse brain late in development (Spas-
sky et al., 2008). It will be interesting to determine if other stem
cells use similar specialized cell structures to translate changes
in the extracellular milieu into modified intracellular signaling re-
sponses. The idea of exquisite regulation of levels of signaling
events has been even more directly shown to be related to
cancer biology, as low levels of Ras and downstream receptor
tyrosine kinase signaling stimulates proliferation while higher
levels initiate cell-cycle arrest and, in some cases, senescence
(Dankort et al., 2007). As mentioned below, the manipulation of
reversible changes in stem cells will depend on the development
of experimental systems capable of ‘‘dialing’’ the levels of gene
products in vivo and in culture settings. Regulation of gene
expression by endogenous microRNAs is hypothesized to oper-
ate based on such a rheostatic mechanism, and the mounting
evidence that microRNAs regulate differentiation may be one
major mechanism that links these concepts (Bartel and Chen,
2004; Wang et al., 2007).
A third aspect of the molecular regulation of stem cells that
received emphasis at this meeting was the importance of the
pathways that regulate the stem cell niche (Sneddon and
Werb, 2007). The niche can be defined as the microenvironment
in which the stem cell resides that specifies lineage potency and
self renewal. The niche is defined both by surface molecules
expressed on adjacent cells and by soluble and adherent com-
ponents in the extracellular surroundings. Therefore, the niche
model defines methods of extrinsic regulation of stem cell
behavior and position. This concept clearly spans stem cells in
distinct organisms and diverse environments during develop-
ment, after injury, with age, in cancer stem cells and also raises
therapeutic implications. The niche can actually specify the num-
bers of stem cells, as was demonstrated in work from Judith
Kimble. She described how a single cell in the distal tip of the
C. elegans germ cell organ controls the number and location of
germ line stem cells and presented evidence that Wnt signals
participate in this regulation. Using another model, Thomas
Rando indicated that Wnt can be involved in the extrinsic sup-
pression of muscle stem cell function with age and also showed
that the dominant pathway controlling this population switches
from Notch to Wnt during the aging process (Brack et al.,
2007, 2008). An obvious implication of niche-mediated control
of stem cells is that non-stem cells may acquire stem cell prop-
erties if they happen to fall into the correct niche. Therefore, it
seems conceivable that cancer stem cells could emerge if
non-stem cells encounter an optimal microenvironment within
the tumor mass or in surrounding normal tissues. In other words,
an extrinsic ‘‘reprogramming’’ of more committed bulk cells back
into stem cells may be possible. Given that cancer stem cells
often exhibit blocked differentiation, this reversion process
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(Harvard Medical School, Dana-Farber Cancer Institute, and
Children’s Hospital, Boston, MA) stressed that reprogramming
of normal cells into ES-like cells may require both driving the plu-
ripotent state and simultaneously preventing differentiation.
Coordination of these two processes may be achieved in re-
sponse to altered expression of epigenetic regulators, some
examples of which have been shown to be elevated in cancer.
Reprogramming requires a precise orchestration to balance plu-
ripotency with differentiation, and perturbation of this balance
could lead to the acquisition of aberrant stem cell programs in
non-stem cells. Fred de Sauvage (Genentech, Inc.) presented
some of his company’s recent progress in developing cancer
therapeutics based on Hedgehog pathway functions in cancer
cells and in niche cells. His comments underscored that future
therapeutic manipulations will need to consider the combined
molecular aspects of niche and stem cell regulation.
Technologies Needed
Beyond all the insight gained from the studies described above
and elsewhere, it is clear from the panel discussion that new tech-
nologies are needed to elaborate on the intersections of stem cell
biology and cancer. First, as discussed by Sean Morrison, Zena
Werb (University of California, San Francisco, CA), Shahin Rafii
(Weill-Cornell Medical College, New York, NY), and others, there
are considerable technical limitations inherent in the assay(s)
used to detect cancer stem cells. The typical method involves
cell sorting based on surface molecule expression and subse-
quent transplantation of the isolated population(s) into immuno-
compromised mice (Purton and Scadden, 2007). However, this
paradigm cannot fully predict the potential of a given population,
or subset therein, in human subjects or in the absence of manip-
ulation and, thus, may not reflect the true activity of the putative
cancer stem cell under examination. For example, improved
animal models and culture conditions will depend on new
developments in order to mimic the stromal components that
accompany cancer cells in their normal environment. One solu-
tion discussed by Max Wicha (University of Michigan, Ann Arbor,
MI), particularly for breast cancer stem cell work, was his labora-
tory’s use of the protocol established by Kupperwasser et al. to
‘‘humanize’’ the mouse mammary gland. In this model, human
mammary gland stromal cells are introduced in the graft to en-
courage the growth of both normal human mammary gland
stem cells, as well as breast cancer samples from patients
(Kuperwasser et al., 2004). Possible technical advances that
may contribute to the design of improved animal models include
the development of polymers, growth factors, or other reagents.
When combined with the identification of appropriate tissue-spe-
cific stromal components and the establishment of methods for
their purification, this collection of materials will likely be useful
for studies using human samples. Clearly, advancing the ability
to mimic the stroma of stem cells will require a more thorough
characterization of the tumor microenvironment and the niche
for normal stem cells. Until improved, humanized models are
available, the study of endogenous murine tumors, which can
more easily be manipulated in syngeneic and/or immune com-
promised murine transplant recipients, will be critical to evaluate
in parallel with patient tumor samples, as demonstrated by Jeff
Rosen (Baylor College of Medicine, Houston, TX). As well, devel-opment of better culture systems that more faithfully read out
stem cell behavior in precisely defined conditions is urgently
needed for biologic and therapeutic studies.
In addition, discussions at the symposium often underscored
that our current understanding of the nature of stem cells in mul-
tiple tissues and situations and how those populations relate to
a given type or subtype of cancer is still rudimentary. Therefore,
while not a specific technological development, more studies to
understand the basic biology of these cells, as well as defining
the hierarchy in different normal tissues, was identified as an-
other absolutely necessary advance. As pointed out by Irving
Weissman, we have yet to apply a cellular version of Koch’s pos-
tulates to establish a causal relationship between a specific cell
population and a specific form of cancer; we still do not yet know
the precise identity of, or how to prospectively isolate, the cells
that give rise to most types of tumors. It is also unknown whether
the observed parallels between hematopoietic malignancies and
HSCs will be relevant for solid malignancies of epithelial origin.
For example, as noted by Ron DePinho, hematopoietic cells
may be wired differently than other cells for apoptosis. Similarly,
Zena Werb and Elaine Fuchs noted the crucial role of adhesion
regulation, organization on the basement membrane, and spin-
dle polarity in epithelial cells (for example, see Ewald et al.,
2008). One particular interesting question that no attendee could
answer definitively was why certain tissues seem to be resistant
to cancer, despite rapid proliferation, as in the small intestine.
Could there be a stem cell explanation? Although one can pos-
tulate that the colon may be particularly bombarded by environ-
mental and bacterial toxins that are known to initiate tumors, it
may also be that the small intestine has better intrinsic tumor
suppressor mechanisms in its stem cells. One explanation may
lie in differences in the body’s intrinsic protection for individual
tissues so that they cannot all be affected by the same mecha-
nistic defect. In other words, perhaps multiple quality control
mechanisms are in place in the body’s stem cells. It will therefore
be critical to determine the unique and important mechanisms
that constrain self renewal for each type of stem cell and cancer
cell in distinct tissues.
Second, a key component missing in the current cancer stem
cell ‘‘tool box’’ is the ability to visualize both the tumor stem cells
and the compartments in which they reside. Thus, new methods
for imaging tumors and transplanted cells are required, along
with the development of reporter genes or other biosensors
that will allow for monitoring the activity of normal stem cells
and cancer cells. Owen Witte (University of California, Los
Angeles, CA) outlined the importance of the concept of multi-
scale imaging and monitoring of tumors. This model emphasizes
the need to image the tumor, assess its biological activity, and to
put these in perspective with whole-body, physiological read-
outs that can be monitored in patients to assess drug response
or disease progression. One currently used imaging technology
that can be included in multiscale imaging paradigms is Positron
Emission Tomography (PET) (Radu et al., 2008), which allows tu-
mor imaging based on the metabolic activity of cancer cells. PET
and other imaging systems have made it evident that some
tumors are rapidly growing while others are not. Ironically, the
basis of this technology highlights yet another limitation in the
field that was raised during the panel discussion: our limited
understanding of tumor metabolism. Distinctions between
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stem cells, or even the bulk cancer population itself have not
been made. Thus, an expansion of the repertoire of established
signaling pathways (as discussed above) and their impact on
cell-type-specific metabolism will likely be important.
A third dire need identified for all of stem cell biology, both in
normal tissues and cancerous tissues, is the ability to character-
ize the molecular and biochemical properties of cell populations
at the single-cell level. The field also requires improved methods
to isolate pure populations of defined cells. While the ability to
analyze some changes in single cells may prove challenging in
the short term, some existing methods might now be used to
analyze small numbers of relatively homogeneous cells. For ex-
ample, the ability to characterize gene expression, genetic alter-
ations, epigenetic modifications, and posttranslational events in
specific cellular subpopulations would go a long way toward
answering questions related to the evolution of cancer cells
and cancer stem cells. The development of genetic tools to in-
duce reversible changes in stem cell populations and within
the niche will also aid in testing the importance of specific altered
events that are detected in tumor samples.
Therapeutics
One of the most beneficial aspects of applying stem cell biology
to cancer research is the resulting conceptual advance with re-
spect to designing therapeutic mechanisms to specifically reach
the tumorigenic cells themselves. That is, instead of focusing
predominantly on signals that regulate cell proliferation, thinking
about cancer as a stem cell disease opens new pathways as
potential clinical targets (Wang, 2007). Examples include self-re-
newal (although this process remains somewhat ill-defined at the
molecular level), promoting differentiation, blocking the niche,
targeting key cell surface markers, and enhancing immune sur-
veillance. Proof of principle studies in a variety of different tumor
models indicate that induction of differentiation, blocking the
niche, and attacking cells expressing key surface markers are
all promising anticancer stem cell strategies that can now be
considered. In addition, Jeremy Rich (Duke University, Durham,
NC) reviewed his recent, exciting studies that exploit distinct
properties of cancer stem cells versus bulk cancer cells in their
ability to promote angiogenesis and to restore radiation sensitiv-
ity. Jeff Rosen presented compelling evidence that cancer stem
cells from genetically distinct patient tumors have different
responses to chemotherapy. Irving Weissman also described
exciting work to show that leukemic stem cells exhibit a special
ability to escape immune surveillance mechanisms; this finding
will be of tremendous importance if solid cancer stem cells
also share the same capacity.
Conclusion
Cancer biology and stem cell biology have certainly become,
and will forever be, closely entwined. A vast number of questions
have arisen following the initial reports that identified cancer
stem cells. These remain early days in the field, and many details
and variances have yet to be elucidated. The cancer stem cell
model may not apply to all human cancers, and some mouse tu-
mors may also not fit the paradigm. What is clear, however, is
that these two fields intersect and, in doing so, have engaged
an increasing number of outstanding investigators eager to
150 Cell Stem Cell 3, August 7, 2008 ª2008 Elsevier Inc.test the relationship using their own experimental arsenal.
Discoveries made in cancer stem cell biology will certainly feed
back into an improved understanding of normal stem cells and
tissue homeostasis. A fresh look at cancer from a stem cell
perspective promises to bestow upon the field of oncology an
even deeper understanding of this terrible disease. Without
a doubt, studies of cancer stem cells fall within the lines that
define stem cell biology, and the discipline will not be complete
without them.
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